Skip to main content

Arrowhead Pharmaceuticals, Inc Investor Event Transcript, Nov 18, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR)

The CEO said the Redemplo sNDA for severe hyperglyceridemia was filed November 2nd, with approval possible within six months, perhaps in March-April. Redemplo lowered triglycerides by 80% from baseline, is dosed once a quarter, and carries a list price of $45,000 a year. AI summary

Investor Event Transcript 2026-11-18 For: 2026-09-30
Added on November 18, 2026

Conference Transcript - ARWR 2026-11-18

Maury Raycroft, Analyst — Jefferies

Thank you. Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Vince Anzalone, or Chris, sorry, Chris. Chris Anzalone, the CEO of Arrowhead. Thanks so much for joining us today, Chris. Sure, Craig. And maybe to start off, for those who are new to the story, if you can give a one-minute intro to Arrowhead.

Chris Anzalone, CEO

Sure. So thanks, Kate, for having us. It's always a pleasure to be here and to see all you folks. Arrowhead is an RNAi company, and we have spent the last 15-plus years building out, I think, the broadest platform in RNAi. We can now deliver to seven different cell types, and we've got clinical studies in five of those cell types. We've got 23 individual drug candidates in clinical studies as we speak. About half of those are partnered, half are wholly owned. We have just launched our first drug earlier this year called Redemplo. It's addressing familial colon micranemia syndrome, or FCS. We just filed our SNDA to expand that to include severe hyperglyceridemia. We have star designation, so we expect that to be approved in the March-April time frame or so. Underneath that, we've got a lot of other things we're working on. We've got, we just recently announced data in AROMAP-T. That is our sRNA molecule designed to knock down tau. Importantly, it's not intrathecal injection. It's sub-Q injection. So we saw a clinical proof of concept that we're capable of delivering to the brain, A, and B, that we are capable of knocking down MAPT or tau. That was exciting. We also have a program that is our first dimer. With a single molecule, we are knocking down both PCSK9 to lower LDL cholesterol and APOC3 to lower triglycerides. We expect to move that forward in mixed hyperlipidemia, and we see that as a real opportunity as well. Anyway, that's a thumbnail sketch of who we are right now.

Maury Raycroft, Analyst — Jefferies

Yeah, it's a great intro, and you mentioned March approval, potentially?

Chris Anzalone, CEO

Well, so what they say is it's a six-month process, but they try to do it shorter than that, and so we'll see when we get approved. The SNDA was filed November 2nd, and so sometime up to six months from then.

Maury Raycroft, Analyst — Jefferies

And maybe just talk a little bit about the STAR program and why FDA gave you that.

Chris Anzalone, CEO

Well, so we're the first ones. We're excited about it because it is – I think it was a reflection of the quality of the data that we saw in Shasta 3 and 4, our phase 3 studies in SHTG patients. It was a reflection of the safety profile that we saw that was stellar. And so, you know, we believe that the FDA saw this as an important medicine that should get to patients as quickly as possible.

Maury Raycroft, Analyst — Jefferies

And just talk about the filing package, and are there issues on efficacy, safety, or CMC that could lead to additional FDA questions or potentially extend timelines?

Chris Anzalone, CEO

Yeah, we don't expect that. You know, it's not one of those nail-biting. PIDUFA dates, I don't think. You know, the data in our Phase 3 for FCS was crystal clear. It was unambiguous. You know, we were, you know, the approval endpoint there was simply lowering triglycerides, and we were way overpowered for that. Same thing here for SHTG. It's just a slightly different patient population. It's a much broader patient population. We think there's between 3 and 3.5 million people in the U.S. alone with triglycerides above 500, 150. And so what we saw in shafts three and four was, again, continued, consistent, good efficacy. You know, we saw an 80% reduction of tolyosurids from baseline. You know, I don't think anyone has ever seen anything like that before. We saw an improvement in rates of pancreatitis. That was important. And we saw a good safety profile. Unlike our competitors, we don't see any increase in liver fat. We don't see any meaningful increases in ALTs. We don't see any hypersensitivity, et cetera. And this is dosed once a quarter. So it feels to us like a drug that has a real place, and we look forward to getting there.

Maury Raycroft, Analyst — Jefferies

Got it. And we've got the Tringles label. What are areas of the proposed SHTG label where you think Rendunplo could meaningfully differentiate from Tringles, Whether it's AP language, dosing, or monitoring.

Chris Anzalone, CEO

Sure. So the way I think of Redemplo is simple, safe, and strong. It's simple because it's a simple quarterly injection that does not require, we don't expect to require liver monitoring and then titrate up. Tremgol requires that. It is safe because we don't see any liver fat increases. We don't see hypersensitivity, as I say. We don't see thrombocytopenia. We don't see ALT increases, and it's strong because, you know, we see 80% reduction from baseline of triglycerides, and we saw a clear benefit in decreasing bouts of acute pancreatitis. You know, our NNT for that population with traviscerides above 500 and history of pancreatitis was three. It was three. You know, it takes three patients over the course of 12 months, you know, to stop one bout of pancreatitis. And we think that is, you know, a very compelling number. We have an ongoing study called Shasta 5 that is a longer-term study. It's an event-driven study in high-risk patients, and so I wouldn't be surprised if that NNT, you know, can shrink even further, you know, as we, you know, look out beyond one year of treatment.

Maury Raycroft, Analyst — Jefferies

Got it. And maybe a quick question on SHASTA-5. Is that study, you're going to keep running that to the end, or have you made any decisions on it?

Chris Anzalone, CEO

Yeah, it's a good question we are. So, you know, you could argue that we don't need to because we saw an improvement in pancreatitis risk in SHASTA-3 and 4. But you know what? We think that every time we see an improvement in pancreatitis, that's a good thing for the field. This is an education play. Physicians generally aren't used to looking at triglycerides and thinking of them as bad actors and getting people on therapy. And so the more often we can show the real risk of pancreatitis in these patients and the fact that we can lower that risk, I think, is a good thing. And so we continue to operate that. You know, we're seeing events, and so my expectation is that that goes, you know, into next year, and then we'll see.

Maury Raycroft, Analyst — Jefferies

Got it. And IONIS is at a relatively slow start with Tringolza, and they cut their guidance materially. What have you learned from their launch about where the challenges are, and how could you address those?

Chris Anzalone, CEO

Sure. So one is just communication. You know, I think, you know, we need to be disciplined and not provide revenue guidance before we have, you know, a feeling for how payers are going to react to this. You know, we are having discussions with payers as we speak. I think that's a good thing. My hope is that we can hit the ground running because we're having these discussions now, and so we hope there's not too much of a lag between being approved and then having policies and then coverage. I think we can affect that. That's important. And it's important that as we are launching, that we share important metrics, since revenue early on only tells part of the story. There's three big metrics that I think we'll be talking about. One is number of prescriptions. That's a clear measurement of demand. That has been high for FCS, even higher, in fact, than we expected. So that's a good start. But let's Let's see how that goes with SHTG. Second would be number of prescribing physicians. We've seen good growth there also in FCS. Let's see where that goes with SHTG. And then third would be number of covered lives. I think for FCS right now, we are covered, I think we have covered lives of around 160 million or so. Let's see how fast we can ramp that up with SHTG. You know, we are actively preparing for that launch, and we are, as we mentioned, speaking with payers. But also, us being out in the field with FCS physicians is also important for physicians to learn about the medicine and how it can be used. Even though, you know, we are only selling into FCS, these physicians certainly, you know, have SHTG patients. And so, you know, the more they're used to hearing about this and seeing the benefits of it, I think that will allow us to hit the ground running.

Maury Raycroft, Analyst — Jefferies

Got it. And Ionis has about a 200-person field team in place. Would you have a similarly sized sales force?

Chris Anzalone, CEO

Yeah, similar. Yeah. In fact, we have already largely ramped that up. We have a small additional wave that will be coming in in January, but we are essentially – our commercial team is where it's going to be. And look, this is important. This launch has to be effective. This is a large market, a big opportunity, as I said, between 3 and 3.5 million people with triglycerides above 500. And importantly, we think there's about a million very high-risk individuals. These would be people with triglycerides above 500 with a history of pancreatitis plus those above 880 with no history of pancreatitis. You know, there's a clear need to treat those patients, and so I think it's critical that we hit the ground running and we get this to the patients who need it.

Maury Raycroft, Analyst — Jefferies

Got it. And just a clarification on that point. You had the detailed SHCG data recently in the New England Journal of Medicine publication. You showed a breakdown of AP and also at the AHA by subgroups. How do you think about that, the million patients out there that are high risk, and how many actually have documented prior AP?

Chris Anzalone, CEO

Right. So that's harder to come at than you would think. We think that there are probably a couple hundred thousand people with triglycerides above 500 and the history of pancreatitis. We don't know for sure because there are many reasons for pancreatitis, but we think that TG-related pancreatitis is about that number. And we think there's about 750,000 or 800,000 people of triglycerides above 880. That is a ticking time bomb because we know that as triglycerides, as triglyceride levels increase, you see a fairly linear increase in the risk of pancreatitis. That slope steepens at 500 and steepens again at 880. And so we think everybody above 500 needs to get down below 500 and to the extent possible to normalize at 150. But we absolutely believe that people above 880 need to get down to below 880 and preferably below 500.

Maury Raycroft, Analyst — Jefferies

Got it. And how reliably can you identify that cohort and claim so the commercial team can target them from day one?

Chris Anzalone, CEO

So it's much easier to identify those folks based on triglyceride levels, right? You know, triglycerides are monitored in most lipid panels, and so, you know, most patients have some history of TG levels, and so that's our primary gauge.

Maury Raycroft, Analyst — Jefferies

Anything else you can say on strategic differentiation versus ionis in finding optimal patients?

Chris Anzalone, CEO

Yeah, you know, I think they will be targeting, you know, largely the same patient population that we will. I think that as we transition from FCS to SHTG, the patient profile changes. You know, these SHTG patients are less symptomatic, and so I think in that kind of patient population, A clean safety profile is even more important. Convenience is even more important. You know, look, I Our primary strategy at launch and beyond is building the market, is finding new patients to the class and putting them on or a Demplo. However, I think switches will, over time, be increasingly important, particularly when there does not seem to be a tradeoff. You know, if somebody has been sticking themselves once a month for quite some time and still worry about liver fat and still worries about transaminases and maybe hypersensitivity, if there's no downside to changing and limiting those risks or even eliminating those risks, and also, oh, by the way, you stick yourself once a quarter, not once a month, I think that's pretty compelling for somebody who is not terribly symptomatic.

Maury Raycroft, Analyst — Jefferies

Got it. And, uh... So you said that the opportunity could be $3 to $4 billion. Can you run through your assumptions on how you get there?

Chris Anzalone, CEO

Sure. There's a lot of ways to get there. So that's $3 to $4 billion a year at peak in the United States. Again, just look at the high-risk individuals. You know, look at those patients with triglycerides above 500 and history of pancreatitis plus those with trigs above 800. There's a million people who we believe are desperately in need of therapy. And remember, you know, about a million people with drug hysterides Above 500 are on prescription fish oils. And so while this is an education play, we're not starting from scratch because, you know, clearly that suggests to us that physicians see those million patients, you know, as requiring treatment. And that's just prescription fish oils. That doesn't include over-the-counter. And so just with that high-risk population, you know, our... Our list price is $45,000 a year. You know, you can get to a fairly large number, you know, just penetrating that population. I think, though, that as physicians become more accustomed to seeing triglycerides as bad actors, I think that the penetration starts to expand in that less severe population. So, you know, somebody with triglycerides at 600 or 700 with no history of pancreatitis, you know, clearly that person is severely hyperglyceridemic. Again, normal is 150 milligrams per deciliter, and so we think over time we can start to penetrate that less severe market.

Maury Raycroft, Analyst — Jefferies

Got it, and you mentioned the price at $45,000. That's at a 12.5% premium versus tringles. Talk about that and whether payers are on board with the increased value proposition, or do you have to do more discounting?

Chris Anzalone, CEO

Yeah, so we'll see where it goes with SHTG. We aren't doing very much discounting at all in FCS. You know, the way we view it is, is, is, you know, look, it's, it's. It is unfortunate that triglycerides show up on a regular lipid panel because it makes people think of it as a lipid drug, and so you run to, you know, to comps would be PCSK9 inhibitors. It's nothing like that. This is not an ASCVD drug. This is a pancreatitis drug, and we've always viewed this more analogous to a mass drug, and given the strength of Redempolo, you know, the... The extent of triglyceride lowering, the extent of AP risk reduction, the clean safety profile, we think there's a ton of differentiation there between Tringolza and Redemplo that we should Price at a premium.

Maury Raycroft, Analyst — Jefferies

Got it. And let's talk about some of the data. With the LDL, you see an increase there across the class, although you guys are increasing less than tringolza. Given that 69% of Shasta patients were on statins and baseline LDL was tightly controlled, what happens in the real world patients whose LDL starts at a much higher level than the less than 70? Are there patients where you would expect clinicians to intensify LDL treatment before starting?

Chris Anzalone, CEO

Yeah, you know, let's see where that goes. We're not super concerned with that because when we do see increases in LDL, it is at very, very high levels of triglycerides, you know, in the thousands, and those patients generally have low LDL to begin with, quite low, in fact. In the more traditional severe hyperglyceridemia market, you know, of between 5 and 800 or so, you don't see much movement in LDL.

Maury Raycroft, Analyst — Jefferies

Makes sense. And going back to Shasta 5, once you get that data, if it's successful, could that actually increase the value proposition? Could you potentially increase your price based on that?

Chris Anzalone, CEO

I don't think so. I think that that data will be nice to have for marketing in Europe and also just increasing the story that we're capable of decreasing the risk of pancreatitis.

Maury Raycroft, Analyst — Jefferies

Got it. And FCS, it's ultra rare, but your launch looks strong on the leading indicators, including patient starts and prescriber breadth, but revenue conversions taking longer. Are there technical issues behind this, or what are some of the explanations?

Chris Anzalone, CEO

No, it's just time. You know, it has just taken us a little bit of time, you know, to have policies in place and have coverage in place to make that process smooth, you know, from a prescription being written and a paid shipment. You know, that, for me, I'm not worried that that will not happen. I'm just more focused on getting that to happen more quickly, and so we're getting there. We've had, you know, we've had breakthroughs with payers over the last couple weeks to keep that moving, and so we feel good about that.

Maury Raycroft, Analyst — Jefferies

Got it. And just as greater awareness around the drug spreads out there and with the SHTG data that's out there, would you expect to see an inflection in FCS over the next two quarters ahead of your approval for SHTG?

Chris Anzalone, CEO

I don't know the answer to that. You know, I would not expect to see a big uptick in prescriptions compared to now. I think we'll continue to see good increases. You know, we are at, you know, 50 to 60 new prescriptions every month. I'm sorry, every week, and that feels pretty good. But, you know, we have competition in SHTG now that would make it easier for some physicians just to prescribe Tringolza rather than Rodempolo, right? And so, you know, that's a – I guess that's a confounding influence. And so I would expect, you know, continued growth but not, you know, not an inflection point necessarily between now and March, April.

Maury Raycroft, Analyst — Jefferies

Got it. Okay. Okay, so let's shift gears, talk about some of the other programs in the pipeline with Aerodimer. I thought the data at AHA looked good with the SAD data showing they can get knocked down as good as single agents. When should we expect to see the MAD data and what efficacy, duration, and tolerability are looking for?

Chris Anzalone, CEO

Yeah, so we'll have MAD data in likely the first half of 27. And as you say, you know, we were really encouraged by that. So the idea was this. You know, we know the PCSK9 inhibition is a good lowering agent of LDL, and LDL is the most validated biomarker on God's green earth. So we thought if we could add to that the ability to lower AFOC3 and therefore lower triglycerides, we could treat this mixed hyperlipidemia population that has both elevated LDL and triglycerides in a more complete fashion. You know, people are, there's an awful lot of evidence that triglycerides, you know, triglyceride-rich lipoproteins, remnant cholesterol, are all potentially, you know, more atherogenic even than LDL cholesterol. It's never been interrogated because no one's been able to lower triglycerides to the extent that we can. And so we thought if you combine those two, you've got something that could be very powerful. And from a regulatory pathway standpoint, you know, we believe that we can see approval based solely on LDL reduction. All the PCSK9s were first approved solely on LDL reduction, and so that is a fairly rapid to registration path. You know, that's a year-long study. I think we can start that phase three fairly quickly, and then what comes out the other side of this is a complete or a quote-unquote complete therapy for these mixed hyperlipidemia patients. You know, the value proposition is, you know, you get, you know, similar LDL reduction as you get with PCSK9s, But oh, by the way, you get triglyceride reduction for free. That's pretty compelling and will allow us to treat a whole swath of folks. We think about 20 million people in the U.S. with mixed cyber lipidemia where there is not that complete treatment.

Maury Raycroft, Analyst — Jefferies

Makes sense. And the two targets, they generally move together, but there's a lot of patient heterogeneity out there. How much patient-level variability is acceptable before the fixed ratio in nature of the dimer becomes a limitation?

Chris Anzalone, CEO

So, yeah, we're not so worried about that. You know, what we've seen is similar knockdown. And so what we are focused on in the SAD and what we will be focused on in the MAD is not just LDL reduction and triglyceride reduction, but ApoB reduction. And ApoB is probably the truer marker of how we're doing. And at least so far, after SAD, you know, we see better ApoB reduction than PCSK9 inhibitors and quite similar LDL reduction as PCSK9 inhibitors. And so I think we're off to a great start.

Maury Raycroft, Analyst — Jefferies

And maybe talk about the registrational path a little bit more. I guess what would be the fastest path in the cleanest or the exact population that would get to the cleanest results?

Chris Anzalone, CEO

Right. So, so, so, um, um. Um, The population would be, you know, those patients with mixed hyperlipidemia, you know, elevated LDL and elevated triglycerides. What that means, we'll see, you know, is that, you know, is that LDL above 70 or LDL above 55? We'll see. And then triglycerides, you know, most patients will probably be in the 200 to 250 range or so. But, of course, you know, we'll go all the way up to, you know, to 499. And there's a lot of those patients out there. And so I don't think recruiting that's going to be difficult, and an LDL biomarker study would be a year-long study. And so I think we could enroll that quite quickly and get through that, you know, quite quickly.

Maury Raycroft, Analyst — Jefferies

Got it. And let's talk about the AeroMapT. You showed nice proof of concept there with sub-Q delivery. What are next steps for that program, and when could we potentially get a data update in 2027?

Chris Anzalone, CEO

Yeah, those are really exciting data, and those are just, you know, single exposure data. You know, we will have MAD data in the first half, I guess, of 27, I mean, healthy volunteers. What we saw was good knockdown of tau as assessed in the cerebral spinal fluid. I think that only tells part of the story, though, right? You know, we're seeing good knockdown, but what we assume we are also seeing is broad distribution. What we saw in non-human primates was, you know, broad, consistent distribution around the brain and knocking down tau. That's super important. You know, if you do an intrathecal injection, you'll see a lot of knockdown on the cord and then maybe a little bit north of that, but you don't see a lot of broad brain coverage. We expect to get that. And, again, we had that in NHPs. So let's see what the MAD data look like. We're off to a really good start. You know, there's increasingly good data coming out of Biogen, you know, in Alzheimer's. In fact, just yesterday, there was more data there that looked, you know, quite encouraging. But also, let's remember that there are other primary telepathies that we can go after where there's a faster regulatory pathway. You know, look at PSP, look at FTD. You know, my expectation is that we could potentially start a Phase III in FTD, you know, sometime towards the end of next year. That would be a relatively fast study and a relatively quick way to get this into patients who need it relatively, you know, fast.

Maury Raycroft, Analyst — Jefferies

Yeah, makes sense. And let's talk about obesity briefly. You're going to have a data update by year-end. Talk about how many patients we should expect with that update, and have you gotten regulatory clarity on next steps for this program?

Chris Anzalone, CEO

Sure. So we'll have more data on inhibiting and ALK7. Inhibiting is the liver target. ALK7 is adipose target. We haven't shown much ALK7 data yet, so that will be the bigger disclosure, I guess. Yes. Inhibony is looking more and more like a MASH drug. You know, we're seeing better than 60 or 70 or so percent reduction in liver fat with inhibony in combination with terzepatide. It was really stunning. And so we are exploring what phase twos would look like in MASH there. ALK7, we're looking forward to seeing these data and potentially pushing those forward into other obesity studies in 2027.

Maury Raycroft, Analyst — Jefferies

Got it. And maybe just in closing, talk about just whether there could be additional BD and just key catalysts ahead that investors should be focusing on.

Chris Anzalone, CEO

Sure. So, yes, there could be more BD ahead. You know, we've got this discovery engine that is second to none and extraordinarily productive, and we can do things that no one else can do. We can deliver all the nucleotides to the brain. We know that now in humans. I think there's a lot of value there. We can deliver to adipose tissue. We can deliver to muscle, to cardiomyocytes, to, you know, to liver, of course. You know, we have good broad coverage, and so I think there's good discovery partnerships to be done there. On catalysts, you know, we'll have more obesity data by the end of this year. We'll have data in Alzheimer's patients with MAPT throughout 2027, both knockdown as well as tau-pet data. We'll have more dimer data in the first half, I guess, of 2027 in mixed hybrid lipidemia patients. We think that we could see an approval of RADEMPLO in SHTG in March, April time frame, something like that. We don't have our PDUPA date yet, but something around then. We will complete the Phase III study of Zodaciran. That's our ANG-PTL3 program against HOFH. That phase three will be done sometime in the middle of the year, and so my expectation is we'll file an NDA there by the end of next year. That's a big move. And then let's see how the Redempola launch goes. As I mentioned, we are focused on that like a laser, and my expectation is that that should be a good launch. Chris, thanks so much for joining us today. Great speaking to you.